332 related articles for article (PubMed ID: 23339305)
1. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
3. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
4. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
5. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
6. Thermal stability threshold for amyloid formation in light chain amyloidosis.
Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M
Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061
[TBL] [Abstract][Full Text] [Related]
7. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
8. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
9. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
Kim YS; Cape SP; Chi E; Raffen R; Wilkins-Stevens P; Stevens FJ; Manning MC; Randolph TW; Solomon A; Carpenter JF
J Biol Chem; 2001 Jan; 276(2):1626-33. PubMed ID: 11050093
[TBL] [Abstract][Full Text] [Related]
10. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
11. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
Martin DJ; Ramirez-Alvarado M
Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
[TBL] [Abstract][Full Text] [Related]
12. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.
Blancas-Mejía LM; Tischer A; Thompson JR; Tai J; Wang L; Auton M; Ramirez-Alvarado M
J Mol Biol; 2014 Jan; 426(2):347-61. PubMed ID: 24157440
[TBL] [Abstract][Full Text] [Related]
13. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
14. Systemic amyloidoses.
Blancas-Mejía LM; Ramirez-Alvarado M
Annu Rev Biochem; 2013; 82():745-74. PubMed ID: 23451869
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.
DiCostanzo AC; Thompson JR; Peterson FC; Volkman BF; Ramirez-Alvarado M
J Biol Chem; 2012 Aug; 287(33):27997-8006. PubMed ID: 22740699
[TBL] [Abstract][Full Text] [Related]
16. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
17. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture.
Sikkink LA; Ramirez-Alvarado M
Cell Death Dis; 2010 Nov; 1(11):e98. PubMed ID: 21368874
[TBL] [Abstract][Full Text] [Related]
19. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
20. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
